cancer drugs

We can ill afford more of the same from these institutions. The stakes are too high, and the fallout is too great, for the status quo to endure. We deserve justice, not more excuses and more attempts to deprive us of the medicines we have a right to receive.
Personally, I have always found it difficult to believe that pharmaceutical companies were in the business of cancer research
"This deal is going to end up looking either very smart or very stupid."
This little-known practice is driving up healthcare costs.
According to a new study in JAMA, there is no evidence that the majority of the U.S. Food and Drug Administration-approved cancer drugs over the last five years work.
The fight over prescription drug prices is only just beginning.
What the 21st Century Cures Act ignores is the prevailing, patient agnostic approach to drug development. We need to move toward a patient-centric approach to drug development and approval, and we should start with cancer treatments.
We are in a different time period thanks to scientific discovery. Our health care system and our views of what cancer looks like need to expand to match up with where we are.
LONDON/NEW YORK, April 28 (Reuters) - U.S. drugmaker Pfizer Inc approached Britain's AstraZeneca Plc two days ago to reignite
"You feel helpless, almost like the world's gone mad," she recalled. "This isn't happening. Surely, in the U.S. and the U.K
I'm from Bangladesh and 27 years old. I was born in a society where anyone hardly heard the word C-A-N-C-E-R. So in face of impossible odds my physician suggested chemotherapy accompanied by Rituxan (a biologic drug), but I was unable to afford it because the drug costs a fortune.
In their Intellectual property case, the pharmaceutical company Novartis was asking to block a generic form of their cancer drug Gleevec from being created and sold by India. As a writer and also a person living with chronic myelogenous leukemia, I understand both sides of the battle.
But what if you want to incentivize investment in bold new drugs instead of me-too drugs? What if you want to encourage research into new areas that tangibly improve people's health? Then maybe, like India, you would only grant patents when that higher standard is met.
Statisticians and statistics are even more fundamental in this era of personalized medicine, as sponsors seek to target treatment to patients most likely to benefit and develop "adaptive" study designs to identify these patients sooner.
Don't get me wrong. We must continue to support the goal of conquering cancer. But we must ask the National Cancer Institute to allocate more funding for prevention, and we must research better, more accurate diagnostics.
The realities of pharmaceutical research are brutal, consisting of decade-and-a-half long timescales, mind-numbing costs and exceedingly long, soul-crushing odds of success. In the fight against cancer, this rings especially true.
Watch the video footage below He's pleaded not guilty to charges of four counts of grand theft, two counts of trafficking